全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Zhou L , Ren Y , Wang X ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2019, Vol.Volume 12, pp.5305-5309DOAJ
摘要:... 4Burning Rock Biotech, Guangzhou, People’s Republic of China*These authors contributed equally to this workAbstract: Afatinib has improved the prognosis of epidermal growth factor receptor-positive advanced non-small cell lung cancer and has been explored in the treatme...
作者:Jing Liu , Bo Jin , Hang Su ...
来源:[J].BMC Cancer(IF 3.333), 2019, Vol.19 (1), pp.1-6DOAJ
摘要:... This study aimed to report a case baring acquired EGFR L858R/L718Q mutation in the central nervous system induced by osimertinib, which was successfully overcome using afatinib. Case presentation A 65-year-old female patient was diagnosed with stage IV non-small-cell lung ade...
作者:Yan Zhang , Changyuan Wang , Zhihao Liu ...
来源:[J].Pharmacological Reports(IF 1.965), 2018, Vol.70 (2), pp.243-250Elsevier
摘要:Abstract(#br)Background(#br)Afatinib is an irreversible multi-targeted TKI, used in the treatment with EGFR mutated non-small cell lung cancer (NSCLC). The purpose of this study is to explore the molecular pharmacokinetic mechanism underlying the effect of P-gp inhibitors on ...
作者:Victor H. F. Lee , Dennis K. C. Leung , Tim-Shing Choy ...
来源:[J].BMC Cancer(IF 3.333), 2016, Vol.16 (1)Springer
摘要:... We prospectively evaluated the efficacy and safety of afatinib in Chinese patients who previously failed first-generation TKI and chemotherapy under a compassionate use program (CUP) and compared to the erlotinib cohort.(#br) Methods(#br)Patients who suffered from metasta...
作者:Hirsh V
来源:[J].OncoTargets and Therapy(IF 2.073), 2017, Vol.Volume 10, pp.2513-2526DOAJ
摘要:... In this context, the recent availability of the checkpoint inhibitors nivolumab and pembrolizumab, the anti-VEGFR2 antibody ramucirumab (combined with docetaxel), and the ErbB-family blocker afatinib for the treatment of relapsed/refractory SqCC of the lung represent major ...
作者:Raghupathy Vengoji , Muzafar A. Macha , Rama Krishna Nimmakayala ...
来源:[J].Journal of Experimental & Clinical Cancer Research(IF 3.066), 2019, Vol.38 (1), pp.1-13DOAJ
摘要:... Here, we evaluated the efficacy of pan-EGFR inhibitor afatinib and Temozolomide (TMZ) combination on GBM in vitro and in vivo. Methods We analyzed the effect of afatinib and temozolomide (TMZ) combination on GBM cells U87MG and U251 engineered to express wild type (WT) EGFR, ...
作者:Yan Zhang , Changyuan Wang , Zhihao Liu ...
来源:[J].Pharmacological Reports(IF 1.965), 2018, Vol.70 (2), pp.243-250Springer
摘要:Abstract(#br)Background(#br)Afatinib is an irreversible multi-targeted TKI, used in the treatment with EGFR mutated non-small cell lung cancer (NSCLC). The purpose of this study is to explore the molecular pharmacokinetic mechanism underlying the effect of P-gp inhibitors on ...
作者:Abdulla Al Mamun Bhuyan , Florian Lang
来源:[J].Cellular Physiology and Biochemistry(IF 3.415), 2018, Vol.47 (3), pp.1259-1273DOAJ
摘要:Background/Aims: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor afatinib is primarily utilized for the treatment of non-small cell lung carcinoma. The drug is at least partially effective by triggering suicidal tumor cell death. Side effects of afatinib...
作者:Kazuo Tamura , Toshihiro Nukiwa , Akihiko Gemma ...
来源:[J].International Journal of Clinical Oncology(IF 1.727), 2019, Vol.24 (8), pp.917-926Springer
摘要:Abstract(#br) Background(#br)This prospective, post-marketing observational study in Japanese patients aimed to evaluate the safety and effectiveness of daily afatinib use in general practice.(#br) Methods(#br)This non-interventional study (NCT02131259) enrolled treatment-naïv...
作者:Ichiki M , Wataya H , Yamada K ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2017, Vol.Volume 10, pp.5107-5113DOAJ
摘要:Masao Ichiki,1 Hiroshi Wataya,2 Kazuhiko Yamada,3 Nobuko Tsuruta,4 Hiroaki Takeoka,1 Yusuke Okayama,1 Jun Sasaki,1 Tomoaki Hoshino3 1Department of Respiratory Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, 2Division of Internal Medicine, Saiseikai Fukuoka General Hospital, Fukuoka City, 3Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University, Kurume City, 4Department of Respiratory Medicine, Hamanomachi Hospital, Fukuoka City, Fukuoka, Japan Purpose: Diarrhea and oral mucositis induced by afatinib...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×